Literature DB >> 10022902

Different regulation of the p53 core domain activities 3'-to-5' exonuclease and sequence-specific DNA binding.

F Janus1, N Albrechtsen, U Knippschild, L Wiesmüller, F Grosse, W Deppert.   

Abstract

In this study we further characterized the 3'-5' exonuclease activity intrinsic to wild-type p53. We showed that this activity, like sequence-specific DNA binding, is mediated by the p53 core domain. Truncation of the C-terminal 30 amino acids of the p53 molecule enhanced the p53 exonuclease activity by at least 10-fold, indicating that this activity, like sequence-specific DNA binding, is negatively regulated by the C-terminal basic regulatory domain of p53. However, treatments which activated sequence-specific DNA binding of p53, like binding of the monoclonal antibody PAb421, which recognizes a C-terminal epitope on p53, or a higher phosphorylation status, strongly inhibited the p53 exonuclease activity. This suggests that at least on full-length p53, sequence-specific DNA binding and exonuclease activities are subject to different and seemingly opposing regulatory mechanisms. Following up the recent discovery in our laboratory that p53 recognizes and binds with high affinity to three-stranded DNA substrates mimicking early recombination intermediates (C. Dudenhoeffer, G. Rohaly, K. Will, W. Deppert, and L. Wiesmueller, Mol. Cell. Biol. 18:5332-5342), we asked whether such substrates might be degraded by the p53 exonuclease. Addition of Mg2+ ions to the binding assay indeed started the p53 exonuclease and promoted rapid degradation of the bound, but not of the unbound, substrate, indicating that specifically recognized targets can be subjected to exonucleolytic degradation by p53 under defined conditions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10022902      PMCID: PMC84008          DOI: 10.1128/MCB.19.3.2155

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  69 in total

Review 1.  The dual role model for p53 in maintaining genomic integrity.

Authors:  F Janus; N Albrechtsen; I Dornreiter; L Wiesmüller; F Grosse; W Deppert
Journal:  Cell Mol Life Sci       Date:  1999-01       Impact factor: 9.261

2.  Monoclonal antibody analysis of p53 expression in normal and transformed cells.

Authors:  J W Yewdell; J V Gannon; D P Lane
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

3.  Monoclonal antibodies specific for simian virus 40 tumor antigens.

Authors:  E Harlow; L V Crawford; D C Pim; N M Williamson
Journal:  J Virol       Date:  1981-09       Impact factor: 5.103

4.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

5.  SV40 T antigen abrogates p53-mediated transcriptional activity.

Authors:  D Jiang; A Srinivasan; G Lozano; P D Robbins
Journal:  Oncogene       Date:  1993-10       Impact factor: 9.867

6.  Tumour suppressor genes. No room at the p53 inn.

Authors:  J A Pietenpol; B Vogelstein
Journal:  Nature       Date:  1993-09-02       Impact factor: 49.962

7.  Human p53 binds DNA as a protein homodimer but monomeric variants retain full transcription transactivation activity.

Authors:  M Tarunina; J R Jenkins
Journal:  Oncogene       Date:  1993-11       Impact factor: 9.867

8.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.

Authors:  J W Harper; G R Adami; N Wei; K Keyomarsi; S J Elledge
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

9.  Precise epitope mapping of the murine transformation-associated protein, p53.

Authors:  A Wade-Evans; J R Jenkins
Journal:  EMBO J       Date:  1985-03       Impact factor: 11.598

10.  Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma.

Authors:  A B DeLeo; H Shiku; T Takahashi; M John; L J Old
Journal:  J Exp Med       Date:  1977-09-01       Impact factor: 14.307

View more
  9 in total

1.  Role of tumor suppressor p53 domains in selective binding to supercoiled DNA.

Authors:  Marie Brázdová; Jan Palecek; Dmitry I Cherny; Sabina Billová; Miroslav Fojta; Petr Pecinka; Borivoj Vojtesek; Thomas M Jovin; Emil Palecek
Journal:  Nucleic Acids Res       Date:  2002-11-15       Impact factor: 16.971

2.  p53 regulates its own expression by an intrinsic exoribonuclease activity through AU-rich elements.

Authors:  Sanaz Derech-Haim; Yael Friedman; Amnon Hizi; Mary Bakhanashvili
Journal:  J Mol Med (Berl)       Date:  2020-02-04       Impact factor: 4.599

3.  Dissection of the sequence-specific DNA binding and exonuclease activities reveals a superactive yet apoptotically impaired mutant p53 protein.

Authors:  Jinwoo Ahn; Masha V Poyurovsky; Nicole Baptiste; Rachel Beckerman; Christine Cain; Melissa Mattia; Kristine McKinney; Jianmin Zhou; Andrew Zupnick; Vanesa Gottifredi; Carol Prives
Journal:  Cell Cycle       Date:  2009-05-15       Impact factor: 4.534

4.  Skp2B overexpression alters a prohibitin-p53 axis and the transcription of PAPP-A, the protease of insulin-like growth factor binding protein 4.

Authors:  Harish Chander; Max Halpern; Lois Resnick-Silverman; James J Manfredi; Doris Germain
Journal:  PLoS One       Date:  2011-08-04       Impact factor: 3.240

Review 5.  p53 Acetylation: Regulation and Consequences.

Authors:  Sara M Reed; Dawn E Quelle
Journal:  Cancers (Basel)       Date:  2014-12-23       Impact factor: 6.639

6.  Transcriptional activation of p21Waf1 contributes to suppression of HR by p53 in response to replication arrest induced by camptothecin.

Authors:  Larisa Y Romanova; Frederick Mushinski; Alexander L Kovalchuk
Journal:  Oncotarget       Date:  2018-05-22

Review 7.  The Tip of an Iceberg: Replication-Associated Functions of the Tumor Suppressor p53.

Authors:  Vanesa Gottifredi; Lisa Wiesmüller
Journal:  Cancers (Basel)       Date:  2018-07-28       Impact factor: 6.639

Review 8.  Exonucleases: Degrading DNA to Deal with Genome Damage, Cell Death, Inflammation and Cancer.

Authors:  Joan Manils; Laura Marruecos; Concepció Soler
Journal:  Cells       Date:  2022-07-09       Impact factor: 7.666

9.  Physical and functional interactions between human mitochondrial single-stranded DNA-binding protein and tumour suppressor p53.

Authors:  Tuck Seng Wong; Sridharan Rajagopalan; Fiona M Townsley; Stefan M Freund; Miriana Petrovich; David Loakes; Alan R Fersht
Journal:  Nucleic Acids Res       Date:  2008-12-09       Impact factor: 16.971

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.